MISSISSAUGA, ON, Sept. 1, 2011 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, announced it will present at two upcoming healthcare conferences in September.
Nuvo management will present at the Stifel Nicolaus Healthcare Conference 2011 in Boston on September 8th, 2011 at 9:45 am EDT.
A live audio webcast of the Company's presentation at this conference will be accessible from the Nuvo Research website. Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast. An audio archive of the presentation will be available for 30 days.
Management will also be presenting at the Rodman & Renshaw 13th Annual Healthcare Conference in New York on September 13th, 2011 at 10:00 am EDT.
A live audio webcast of this presentation will also be accessible from the Nuvo Research website. Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast. An audio archive of the presentation will be available for 90 days.
About Nuvo Research Inc.
Nuvo Research is a publicly traded, Canadian specialty pharmaceutical
company, headquartered in Mississauga, Ontario. The Company is
building a portfolio of products for the treatment of pain through
internal research and development and by in-licensing and acquisition.
The Company's Pain Group, located in West Chester, Pennsylvania, is
focused on the development and commercialization of topically delivered
pain products. The Company's product portfolio includes Pennsaid,
Pliaglis and Synera. Pennsaid, a topical non-steroidal
anti-inflammatory drug (NSAID), is used to treat the signs and symptoms
of osteoarthritis of the knee. Pennsaid is sold in the United States
by Mallinckrodt Inc., a Covidien company (NYSE: COV), in Canada by
Paladin Labs Inc. (TSX:PLB) and in several European countries. Pliaglis
is a topical local anesthetic cream, which is U.S. Food and Drug
Administration (FDA) approved to provide topical local analgesia for
superficial dermatological procedures. The Company has licensed
worldwide marketing rights to Pliaglis to Galderma Pharma S.A., a
global specialty pharmaceutical company focused on dermatology. Synera
is a topical patch that combines lidocaine, tetracaine and heat,
approved in the United States to provide local dermal analgesia for
superficial venous access and superficial dermatological procedures and
in Europe, for surface anaesthesia of normal intact skin. Nuvo
currently markets Synera in the United States and its licensing
partner, EuroCept International B.V., has initiated a pan-European
launch of Synera (under the name Rapydan) in several European
countries. Through its subsidiary, Nuvo Research GmbH, based in
Leipzig, Germany, the Company is also developing the compound WF10, for
the treatment of immune related diseases. For more information, please
visit www.nuvoresearch.com.
Forward-Looking Statements
This document contains forward-looking statements. Some forward-looking
statements may be identified by words like "expects", "anticipates", "plans", "intends", "indicates" or
similar expressions. These forward-looking statements, by their nature,
necessarily involve risks and uncertainties that could cause actual
results to differ materially from those contemplated by the
forward-looking statements. Nuvo considers the assumptions on which
these forward-looking statements are based to be reasonable at the time
they were prepared, but caution that these assumptions regarding future
events, many of which are beyond the control of the Company, may
ultimately prove to be incorrect. Factors and risks, which could cause
actual results to differ materially from current expectations, are
discussed in the annual report, as well as in Nuvo's Annual Information
Form for the year ended December 31, 2010. Nuvo disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information or future events,
except as required by law. For additional information on risks and
uncertainties relating to these forward looking statements, investors
should consult the Company's ongoing quarterly filings, annual report
and Annual Information Form and other filings found on SEDAR at www.sedar.com.
SOURCE Nuvo Research Inc.
